

Axle component separated ion-pair recognition by a neutral heteroditopic [2]rotaxane


Richard C. Knighton^a and Paul D. Beer^{a*}

^a Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Mansfield Road, Oxford, OX1 3TA (UK)

E-mail: paul.beer@chem.ox.ac.uk

S1 Experimental

The Calix[4]arene macrocycle precursor was synthesised according to a previously reported procedure,¹ as depicted in Scheme S1.




Scheme S1.1: Synthesis of calix[4]arene macrocycle precursor

The pyridine N-oxide bis-azide threads **2**² and **3**³ and alkyne-functionalised terphenyl stopper **4**⁴ were synthesised as previously described.

Calix[4]arene macrocycle S6

Thallium (III) trifluoroacetate (2.69 g, 4.95 mmol) was suspended in dry CH₂Cl₂ (20 mL) at 0°C under N₂ in the absence of light. A solution of calix[4]arene macrocycle **S6** (563 mg, 0.495 mmol) in CH₂Cl₂ (20 mL) and trifluoroacetic acid (5 mL) was added simultaneously and the reaction was stirred at 0°C for 35 minutes. The reaction was quenched with H₂O (10 mL) and stirred vigorously for 10 minutes. This was repeated twice and the organic layer dried over MgSO₄. Purification by gradient column chromatography (silica; acetone/hexane; 75:25→100:0) and preparative thin layer chromatography (silica; CH₂Cl₂/MeOH, 95:5) afforded **2** as a bright orange solid (172 mg, 33%). ¹H NMR (300 MHz, CDCl₃) δ_H 9.17 (2H, s, ArH), 8.54 (1H, s, ArH), 6.93-6.76 (12H, m, ArH), 6.70 (4H, s, CH), 4.17-4.04 (8H, m, CH, CH₂), 3.98-3.80 (12H, m, CH₂), 3.30 (4H, d, *J* = 12.9 Hz, CH), 1.14 (18H, s, ^{*t*}Bu) ¹³C NMR (75 MHz, CDCl₃) δ_C 186.7, 185.6, 165.3, 153.9, 152.7, 150.9, 147.1, 146.5, 133.1, 129.8, 129.4, 126.9, 115.4, 72.6, 67.2, 67.0, 39.8, 34.1, 32.7, 31.4; ESI-HRMS: found *m/z* = 1076.4323, calculated 1076.4304 for [M + Na]⁺.

Rotaxane 11



Calixdiquinone macrocycle **1** (30.0 mg, 0.0283 mmol) and sodium perchlorate (3.84 mg, 0.0313 mmol) were dissolved in CHCl₃ (10 mL) and stirred under N₂ for 16 hours. Stopper alkyne **4** (30.39 mg, 0.0625 mmol), N-oxide **3** (10.86 mg, 0.313 mmol) Cu^I(MeCN)₄PF₆ (2.08 mg, 0.00554 mmol), tris[(1-benzyl-1*H*-1,2,3-triazol-4-yl)methyl]amine (TBTA)

(2.22 mg, 0.0042 mmol) and diisopropylethylamine (DIPEA) (0.01 mL) were added and the reaction was stirred at ambient temperature for 36 hours under N₂. The reaction was subsequently washed with 0.25 M EDTA_(aq) (3 × 10 mL) and the solvent removed *in vacuo*. Purification by size exclusion chromatography (SX-3; CHCl₃) and preparative thin layer chromatography (silica; CH₂Cl₂/MeOH; 99:1→97:3) afforded the compound as yellow solid (41.5 mg, 62 %). ¹H NMR (500 MHz, CDCl₃) δ_H 9.32 (2H, d, ⁴J = 2.2 Hz, pyridine isophthalamide ArH), 9.08 (1H, t, ⁴J = 2.0 Hz, pyridine isophthalamide ArH), 8.59 (2H, s, pyridine N-oxide isophthalamide ArH), 8.35 (2H, br.s, NH), 7.91 (2H, br.s, NH), 7.75 (2H, s, triazole ArH), 7.46 (1H, s, pyridine N-oxide isophthalamide ArH), 7.25-7.04 (30H, m, stopper ArH), 6.90-6.80 (12H, m, stopper, calix ArH, quinine CH), 6.58 (4H, d, ³J = 8.9 Hz, hydroquinone ArH), 6.31 (4H, d, ³J = 8.9 Hz, hydroquinone ArH), 5.16 (4H, br.s, calix CH, CH₂), 4.38 (4H, t, ³J = 7.0 Hz, CH₂), 4.09 (4H, s, CH₂), 3.96 (4H, s, CH₂), 3.88-3.80 (8H, m, CH₂), 3.41 (4H, s, CH₂), 3.29 (4H, d, ²J = 11.3 Hz, calix CH), 2.22 (4H, s, CH₂), 2.15 (4H, br.s, CH₂), 1.30 (36H, s, ^tBu), 1.11 (18H, s, ^tBu) ¹³C NMR (500 MHz, CDCl₃) δ_C 185.9, 166.3, 162.2, 156.4, 152.9, 152.5, 148.7, 147.9, 147.5, 147.4, 144.6, 144.1, 140.5, 140.3, 133.2, 132.8, 131.4, 130.9, 129.4, 129.0, 127.5, 126.0, 124.4, 123.5, 115.5, 114.4, 113.5, 67.6, 67.2, 63.7, 62.1, 48.3, 40.7, 37.7, 34.5, 34.4, 31.6, 31.6; remaining quaternaries undetected; ESI-HRMS: found *m/z* = 1210.0753, calculated 1210.0764 for [M + 2Na]²⁺.

S2: Characterisation data for [2]rotaxane **5**




Figure S2.1: Assigned ^1H NMR spectrum of heteroditopic [2]rotaxane **5** (500 MHz, CDCl_3 , 298 K)




Figure S2.2: ^{13}C spectrum of heteroditopic [2]rotaxane **5** (125 MHz, CDCl_3 , 298 K)




Figure S2.3: ESI-HRMS heteroditopic [2]rotaxane **5**

S3; Conformational Studies of [2]rotaxane




Figure S3.1: ^1H - ^1H ROESY NMR of [2]rotaxane **5** (500 MHz, CDCl_3 , 298 K)




Figure S3.2: ^1H - ^1H ROESY NMR of [2]rotaxane **5** plus 1 equivalent of sodium triflate (500 MHz, CDCl_3 , 298 K)

S4: ^1H NMR Titration Protocol

Titration experiments were conducted on either a 500 MHz Oxford Instruments Varian Plus or a Bruker Avance III 500 MHz spectrometer at 298 K. Initial sample volumes were 500 μL . The starting host concentration was 1.5 mM for all titrations. All anions were added as their *n*-tetrabutylammonium salts. Cations were added as their non-coordinating salts; lithium hexafluorophosphate, sodium triflate and potassium hexafluorophosphate were used. Seventeen aliquots of the anion guest were added until a total of ten equivalents had been added. Spectra were recorded upon each addition and thorough mixing of the sample.

Stability constants were obtained by analysis of the titration data using WinEQNMR2 data fitting software.⁵ Comparison of the calculated binding isotherm with that obtained experimentally confirmed that in all cases the binding fitted a 1:1 binding model.

S4.1: 1 to 1 [2]pseudorotaxane Studies




Figure S4.1: 1:1 [2]pseudorotaxane formation templated by sodium tetraphenylborate (300 MHz, CDCl_3 , 298 K)




Figure S4.2: Changes in the internal axle proton α of [2]rotaxane **5** upon increasing amounts of anion in the absence of a metal cation ($\text{CDCl}_3/\text{CD}_3\text{OD}$ 4:1, 298 K); points represent data points, continuous lines represent calculated curves)




Figure S4.3: Changes in the internal axle proton α of [2]rotaxane **5** upon increasing amounts of anion in the absence and in the presence of a metal cation ($\text{CDCl}_3/\text{CD}_3\text{OD}$ 4:1, 298 K); points represent data points, continuous lines represent calculated curves)

S5: X-ray Crystallography

Single crystals of calixdiquinone macrocycle **1** were grown by vapour diffusion of diisopropyl ether into a solution of chloroform. Data were collected on using synchrotron radiation on Beam I19 at Diamond Light Source ($\lambda = 0.68890 \text{ \AA}$). The diffractometer was equipped with a Cryostream N₂ open-flow cooling device,⁶ and the data were collected at 100 K. Series of ω -scans were performed in such a way as to collect a half-sphere of data to a maximum resolution of $0.77 \text{ \AA}$. Cell parameters and intensity data (including inter-frame scaling) were processed using CrysAlis Pro.⁷ The structure was solved by charge-flipping using SUPERFLIP,⁸ the output of which was a structure in the spacegroup P -1. Refinement was conducted using full-matrix least-squares on F^2 within the CRYSTALS suite.⁹ Non – hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms were generally visible in the difference map and their positions and displacement parameters were refined using restraints prior to inclusion into the model using ride constraints.¹⁰




Figure S5.1: Single crystal X-ray structure of macrocycle **1** (Non hydrogen bonding hydrogens have been omitted for clarity, ellipsoids plotted at 50 % probability)

Crystallographic data for the structure has been deposited with the Cambridge Crystallographic Data Centre, CCDC: 970552. Copies of these data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data/_request/cif.

S6: References

1. M. D. Lankshear, N. H. Evans, S. R. Bayly and P. D. Beer, *Chemistry – A European Journal*, 2007, 13, 3861-3870.
2. J. M. Mercurio, F. Tyrrell, J. Cookson and P. D. Beer, *Chem. Commun.*, 2013.
3. F. Zapata, O. A. Blackburn, M. J. Langton, S. Faulkner and P. D. Beer, *Chem. Commun.*, 2013, 49, 8157-8159.
4. A. V. Leontiev, C. A. Jemmett and P. D. Beer, *Chemistry – A European Journal*, 2011, 17, 816-825.
5. M. J. Hynes, J. Chem. Soc., Dalton Trans., 1993, 311-312.
6. Cosier, J.; Glazer, A. M. J. *Appl. Cryst.* 1986, 19, 105-107.
7. Agilent Technologies, CrysAlisPro, 2011.
8. L. Palatinus, G. Chapuis, *J. Appl. Cryst.* 1997, 40, 786-790.
9. P. W. Betteridge, J. R. Carruthers, R. I. Cooper, K. Prout, D. J. Watkin, *J. Appl. Cryst.* 2003, 1487.
10. R.I. Cooper, A.L. Thompson, D.J. Watkin, *J. Appl. Crystal.*, 2010, 43, 1017-1022.